Author(s)

Abdulrahman Alsheikh¹, Ahmed Aljedai², Hajer Almudaiheem², Salwa Alaidarous³, Ali Alshehri⁴, Hussein Elbadawi⁵, Saeed Alghamdi¹, Faisal Aljehani⁶, Sami Alobaidi⁶, Talal A. Altuwaijri⁷, Khalid Almatham^4,8, David Strain⁹, Marc Evans¹⁰, Emad R. Issak^11*, Saud Alsifri¹²

¹King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
²Ministry of Health, Riyadh, Saudi Arabia.
³Ministry of National Guards Hospital, Jeddah, Saudi Arabia.
⁴King Fahad Medical City, Riyadh, Saudi Arabia.
⁵My Clinic, Jeddah, Saudi Arabia.
⁶College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
⁷College of Medicine, King Saud University, Riyadh, Saudi Arabia.
⁸College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
⁹University of Exeter Medical School, Exeter, UK.
¹⁰University Hospital Llandough, Cardiff, UK.
¹¹College of Medicine, Ain Shams University, Cairo, Egypt.
¹²Alhada Armed Forces Hospital, Taif, Saudi Arabia.

According to recent epidemiological data, chronic kidney diseases (CKDs) affect approximately 10% of the global population. Like many countries, CKD is a significant public health issue in Saudi Arabia. The prevalence of CKD in Saudi Arabia is estimated to be around 4.5% of the adult population, with a higher prevalence in older age groups. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a class of oral medications used to treat type 2 diabetes mellitus (T2DM). In addition to their glucose-lowering effects, SGLT2i have been shown to have beneficial effects on kidney function in patients with or without T2DM. Therefore, a Saudi task force gathered to develop an explicit, evidence-based consensus on SGLT2i use in CKD Saudi patients. A panel of 14 experts made up a task force. An initial concept proposal was obtained. The proposal was divided into several topics discussed on 24 May 2023. A literature review was carried out. The literature search was completed on 3^rd June 2023. A drafted report was distributed to the entire panel. Approval of the recommendations required consensus, defined as a majority approval (i.e. above 75%). The recommendations were revised to accommodate any differences of opinion until a consensus was reached. Recommendations were finally formulated on 21^st June 2023. Subsequently, the panel reviewed and discussed the supporting rationale of the revised recommendations. This article presents these practical recommendations.

Chronic Kidney Disease, Sodium-Glucose Cotransporter-2 Inhibitors, Adverse Effects, Monitoring, Canagliflozin, Dapagliflozin, Empagliflozin

Alsheikh, A. , Aljedai, A. , Almudaiheem, H. , Alaidarous, S. , Alshehri, A. , Elbadawi, H. , Alghamdi, S. , Aljehani, F. , Alobaidi, S. , Altuwaijri, T. , Almatham, K. , Strain, D. , Evans, M. , Issak, E. and Alsifri, S. (2023) Saudi Consensus on the Usage of Sodium-Glucose Cotransporter-2 Inhibitors on the Management of Chronic Kidney Diseases. International Journal of Clinical Medicine, 14, 525-539. doi: 10.4236/ijcm.2023.1412045.